Pfizer, YaoPharma Sign Global Deal for Oral GLP-1 Candidate Pfizer has signed an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, to advance the development of YP05002, an oral GLP-1 receptor agonist in Phase 1 studies for chronic weight management
It isnt cheap as it comes in at around the 45 mark, more info can be found at Jan Marini here link and purchased from Feel Unique here link.
Chronic Dosing Schedules Acute administration of ALLO improves memory function in one mouse model of AD (197), but other studies using rodent models suggest that chronic exposure to ALLO may actually cause memory deficits and exacerbate disease-related functional impairments (198200)
The FDAs prior warnings regarding the potential elevated risk of medullary thyroid carcinoma associated with GLP-1 RAs may encourage more patients on GLP-1 RA therapy to undergo thyroid ultrasounds, thereby enhancing tumor detection
Remember, consistency, diet, and exercise are the most important factors for achieving your fitness goals
